Clinical outcomes after infusion of CD19-CAR T cells. (A) Swimmers plot depicting the clinical course for each patient, with each lane representing a single patient. Patient 6: the indication for a third CAR T-cell reinfusion was a loss of BCA; the patient achieved BCA again after infusion. (B) EFS and OS of the entire patient cohort (n = 12). EFS was defined as the time from CAR T-cell infusion to NR at 4 weeks after CAR T-cell infusion, relapse, or death, with censoring at the time of the last follow-up. OS was defined by the time from CAR T-cell infusion to death, censoring at the time of the last follow-up. EFS and OS rates were estimated by the Kaplan-Meier method and compared by the log-rank test. (C) Duration of BCA among patients achieving a CR after CAR T-cell therapy. (D) Graphical presentation of outcome and observed toxicities, including disease response in the BM at 4 weeks after CAR T-cell infusion, the highest grade of CRS/NTX, and presence of carHLH. Patients are grouped based on the level of leukemic disease in the BM before CAR T-cell infusion (high: ≥40% morphologic blasts; low: <40% morphologic blasts).